AllDocs -> cancers

Hepatic resection for primary liver cancer at a private community hospital: retrospective study of 61 patients MH Shiu, DLSSiu, WM Hui, HC Yu, KCLam Objective. To review the outcome after surgical resection for primary liver cancer . Design. Retrospective study. Setting. Private community hospital, Hong Kong. Patients. Sixty-one consecutive patients who underwentliverresection for primarycancer from 1992through 1997. Main outcome measures. Clinicopathological features, type of resection, duration of hospital stay, and actuarial overall and disease-free 5-year survival rates. Results. Cirrhosis was present in 46 (75%) of the patients, and 42 (69%) were positivefor hepatitis B surface antigen. The median tumour diameter was 8 cm (range, 1-16cm). Liver resectionsconsisted ofhemihepatectomy (n=37), trisegmentectomy (n=4), segmentectomy (n= 11),and wedge resection (n=9). Postoperative death ...

• Active liver disease (jaundice) • Breast lumps and possible breast cancer • Migraines • Diabetes • Hypertension If none of these are found Depoprovera may be given. If there are any “Yes” answers, you should carefully consider the risks and benefits of Depoprovera use for the particular client. Timing of injection Injectable contraceptives should be given: • Within the first 7 days of the menstrual cycle • Any time during the menstrual cycle if it is certain that the woman is not pregnant. She has no signs or symptoms of pregnancy (e.g. breast tenderness, nausea) and: • Has not had sexual intercourse since her last menses, or • Has been using another reliable contraceptive method consistently and correctly • After the 7th day, only with a back up method preferably condoms, which should be used for 24 hours Postpartum • Breastfeeding mothers: If the women ...

Asian Pacific Journal of Cancer Prevention, Vol 2, 2001 117 Epidemiology of Liver Cancer in Thailand Asian Pacific J Cancer Prev, 2 , 117-121 MINI-REVIEW Introduction During the last 20 years, the leading cause of death in Thailand has changed from infectious diseases to non- communicable diseases. These comprise diseases of heart (including “heart failure”), malignant neoplasms, and accidents and poisonings. Their rates have gradually increased over the past decade. Cancer registries document cases of cancer within a particular region, providing information on how often cancers occur, and on how many people survive their disease. These data are needed for planning and monitoring cancer control strategies and for identifying priorities in public health. The population – based cancer registry records all new cases in ...

Cahaba Government Benefit Administrators A CMS Contracted Fiscal Intermediary 400 E. Court Avenue Des Moines, IA 50309-2017 Liver Disease Revision # RETIRED: 07/31/2003 Contractor's Policy Number OA 98006 THIS POLICY HAS BEEN RETIRED AND IS NO LONGER IN EFFECT. Contractor Name Cahaba Government Benefit Administrators Contractor Number 000011 Contractor Type Fiscal Intermediary LMRP Title HOSPICE - DETERMINING TERMINAL STATUS IN NON- CANCER DIAGNOSES - LIVER DISEASE THIS POLICY HAS BEEN RETIRED AND IS NO LONGER IN EFFECT. AMA CPT Copyright Statement CPT codes, descriptions, and other data only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply CMS National Coverage Policy • Social Security Act, Secs. 1102, 1812(a)(4) ...

Spring 2005 The Fight Against Hepatitis B and Liver Cancer De C al David Chao Denis Lam decal@jrc.berkeley.edu http://jrc.berkeley.edu MCB 98/198, 2 Units P/NP Friday 2-3:30 pm, Location (TBA) Course Description Hepatitis B is currently one of the top five causes of premature mortality for Asian & Pacific Islander Americans (APIA) – yet it is preventable by a vaccine which has been available for over 20 years. The Jade Ribbon Campaign DE-Cal course addresses the issues of hepatitis B and liver cancer , and their impact both here in the United States and abroad in countries such as China. After learning about the virology, biochemistry, and epidemiology of the disease, students will have an opportunity to put their new knowledge about hepatitis B into community practice in this service learning course. Through listening to ...

PROFILE JANUARY 2005 22 SCHOLARLY ACTIVITIES SCHOLARLY ACTIVITIES New drug against liver cancer L iver cancer , also known as Hepatocellular Carcinoma or HCC is one of the five most common human cancers in the world and the second leading cause of cancer death in Hong Kong. A joint research team formed among our Department of Applied Biology and Chemical Technology, HKU’s Centre for the Study of Liver Disease and a commercial partner, has broken new ground in developing a drug to fight against liver cancer . The new drug is developed based on the mechanism of arginine depletion which is believed to be effective in inhibiting tumor growth in HCC without affecting the normal cells. Earlier, PolyU researchers have successfully produced a human recombinant arginase that has a prolonged half-life in the circulation to allow ...

Secondary liver cancer This factsheet is for anyone who has been diagnosed with secondary cancer in the liver that has spread from the breast. It describes what secondary liver cancer is, some of the possible symptoms and treatments that may be used. We hope it answers some of your questions and helps you discuss your options further with your specialist team. You may also find it helpful to read our Secondary breast cancer booklet, which looks at the physical and emotional impact of living with secondary breast cancer . What is secondary liver cancer ? Secondary liver cancer occurs when cancer cells spread from the breast through the blood or lymph system and settle in the liver . You may hear this type of spread described as metastases, recurrence of the cancer , secondary tumours or secondaries. The cells that have settled in the ...

This factsheet is for anyone who has been diagnosed with secondary cancer in the liver that has spread from the breast. It describes what secondary liver cancer is, some of the possible symptoms and treatments that may be used. We hope it answers some of your questions and helps you discuss your options further with your specialist team. You may also find it helpful to read our Secondary breast cancer booklet, which looks at the physical and emotional impact of living with secondary breast cancer . What is secondary liver cancer ? Secondary liver cancer occurs when cancer cells spread from the breast through the blood or lymph system and settle in the liver . You may hear this type of spread described as metastases, recurrence of the cancer , secondary tumours or secondaries. The cells that have settled in the liver are breast cancer cells. It is not the same ...

Table 1.9a - Major ablative procedures associated with cancer of the liver (ICD-9 155) in British Columbia 1999/2000 - 8 11 - - - 5 0 11 - 27.6% 32.4% - - - 38.5% .0% 32.4% - 72.7% 100.0% - - - 45.5% .0% 100.0% 0 7 7 0 0 - - 0 7 .0% 24.1% 20.6% .0% .0% - - .0% 20.6% .0% 100.0% 100.0% .0% .0% - - .0% 100.0% - 11 13 - 0 6 5 0 13 - 37.9% 38.2% - .0% 37.5% 38.5% .0% 38.2% - 84.6% 100.0% - .0% 46.2% 38.5% .0% 100.0% 0 - - 0 0 - 0 0 - .0% - - .0% .0% - .0% .0% - .0% - - ...

• LIVER CANCER • Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2 Dong-Sheng Huang, Ke-Zhen Shen, Jian-Feng Wei, Ting-Bo Liang, Shu-Sen Zheng, Hai-Yang Xie PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(2):204-207 Fax: +86-10-85381893 World Journal of Gastroenterology ISSN 1007-9327 E-mail: wjg@wjgnet.com www.wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER Dong-Sheng Huang, Ke-Zhen Shen, Jian-Feng Wei, Ting-Bo Liang, Shu-Sen Zheng, Hai-Yang Xie, Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, College of Medicine, Hangzhou 310003, Zhejiang Province, China Correspondence to: Dr. Hai-Yang Xie, Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital, College of ...

To learn more about our Asian Hepatitis B - Liver Cancer program, please contact us at: Philadelphia Headquarters Office : Center for Asian Health Department of Public Health College of Health Professions Temple University 1415 N. Broad Street, Suite 116 Philadelphia, PA 19122 Tel: 215-787-5431 Fax: 215-787-5436 Email: atecar@astro.temple.edu Website: www.temple.edu/cah New York City Office: Center for Asian Health Temple University 401 Broadway, Suite 2306 New York City, NY 10013 Tel: 212-219-8449 Asian Tobacco Education, Cancer Awareness and Research (ATECAR) and its affiliates provide: tobacco and cancer prevention and intervention activities, and training and research opportunities for Asian Americans. For Information on ATECAR, call 215-787-5431 For Information on Cancer , call ...

Study on environmental etiology of high incidence areas of liver cancer in China Nian Feng Lin 1 , Jie Tang 1 and Hoteyi S. Mohamed Ismael 2 Subject headings liver neoplasms; etiology; epidemiology; water pollution; environmental carcinogens; nitrosamines; china; geology Lin NF, Tang J, Mohamed Ismael HS.Study on environmental etiology of high incidence areas of liver cancer in China. World J Gastroentero , 2000;6(4):572-576 INTRODUCTION China is a country with a high incidence of liver cancer in some areas [1] . Liver cancer has a wide distribution and threatens human health seriously. A ro ugh estimation shows that out of a population of 1.2 × 10 8 in liver cancer areas patients are more than 1.0 × 10 5 . The environment of the ...

When cells in the liver become abnormal, grow out of control and form a cancerous tumor, the disease is called primary liver cancer , also known as malignant hepatoma or hepatocellular carcinoma. (“Hepato” means “ liver .”) Primary liver cancer is not the same disease as cancer that spreads (metastasizes) to the liver from another part of the body (secondary liver cancer ). The liver is often the site of secondary tumors that result from the spread of cancer from another organ, such as the colon or breast. The cancer cells in the secondary tumor are like those of the original cancer , the primary cancer , which is named for the part of the body in which it began. Thus, cancer that begins in the colon or breast and spreads to the liver is called metastatic colon cancer or metastatic breast cancer . What are ...

Background information regarding Austin Health’s new liver cancer treatment What is the treatment for? Certain advanced and inoperable liver cancers. How does it work? The treatment involves using microscopic radiation beads called SIR-Spheres ® that are injected directly into the liver cancers to destroy tumours within the liver that are otherwise inaccessible and inoperable, while minimising harmful side effects to surrounding healthy tissue. For information on the treatment visit www.sirtex.com Can any one with liver cancer have this treatment? Not everyone is suitable for this treatment and must undergo tests in hospital to determine their suitability. How do I find out if I am suitable for this treatment? Visit www.sirtex.com and printout the information to take to your oncologist ( cancer doctor) to discuss your ...

Disregulation of E-cadherin in transgenic mouse models of liver cancer Diego F Calvisi*, Sara Ladu*, Elizabeth A Conner, Valentina M Factor and Snorri S Thorgeirsson Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, MD, USA E-cadherin is a cell–cell adhesion molecule that plays a pivotal role in the development and maintenance of cell polarity. Disruption of E-cadherin-mediated adhesion represents a key step toward the invasive phenotype in a variety of solid tumors, including hepatocellular carcinoma (HCC). Here, we investigate whether deregulation of E-cadherin occurs along the multistep process of hepatocarcinogenesis in transgenic mouse models, including c-Myc, E2F1, c-Myc/TGF-a and c-Myc/E2F1 mice. Liver tumors from the transgenic mouse lines could be divided into two categories based on E-cadherin levels. Of 28, 20 (71.4%) c-Myc HCCs showed marked reduction of ...

liver cancer Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance Elefsiniotis IS, Pantazis KD, Ilias A, et al. Eur J Gastroenterol Hepatol 2004; 16(6): 593-598 Tamoxifen-induced hepatotoxicity has not been investigated in breast cancer patients with pre-existing liver steatosis. The aim of the study was to investigate the most common predisposing factors for non-alcoholic fatty liver disease in breast cancer patients with liver steatosis, treated with adjuvant tamoxifen therapy, in order to evaluate their role in the appearance of tamoxifen induced hepatotoxicity. A series of clinical and laboratory evaluations, including an oral glucose tolerance test, were performed in 60 women with breast ca ncer and liver steatosis before the beginning of adjuvant tamoxifen treatment and every 6 months ...

Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance Elefsiniotis IS, Pantazis KD, Ilias A, et al. Eur J Gastroenterol Hepatol 2004; 16(6): 593-598 Tamoxifen-induced hepatotoxicity has not been investigated in breast cancer patients with pre-existing liver steatosis. The aim of the study was to investigate the most common predisposing factors for non-alcoholic fatty liver disease in breast cancer patients with liver steatosis, treated with adjuvant tamoxifen therapy, in order to evaluate their role in the appearance of tamoxifen induced hepatotoxicity. A series of clinical and laboratory evaluations, including an oral glucose tolerance test, were performed in 60 women with breast cancer and liver steatosis before the beginning of adjuvant tamoxifen treatment and every 6 months during treatment. Tamoxifen-induced ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(16):2455-2456 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2004 by The WJG Press ISSN 1007-9327 • CASE REPORT • A case of leptospirosis simulating colon cancer with liver metastases Alessandro Granito, Giorgio Ballardini, Marco Fusconi, Umberto Volta, Paolo Muratori, Vittorio Sambri, Giuseppe Battista, Francesco B. Bianchi Alessandro Granito, Giorgio Ballardini, Marco Fusconi, Umberto Volta, Paolo Muratori, Francesco B. Bianchi, Departments of Internal Medicine, Cardioangiology, Hepatology, Alma Mater Studiorum - University of Bologna, Italy Vittorio Sambri, Department of Clinical and Experimental Medicine, Section of icrobiology, Alma Mater Studiorum - University of Bologna, Italy Giuseppe Battista, Department of Radiology, ...

Cancer in Northern Ireland 1993 - 2001: A Comprehensive Report 37 7: Cancer of the Liver & Intrahepatic Bile Ducts (C22) Incidence In 2001, cancer of the liver was the seventeenth most common cancer in males and nineteenth commonest in females. On average, 29 males and 26 females were diagnosed as having cancer of the liver each year, accounting for about 1% of all cancers registered. Age The median age at diagnosis was 69 years for males and 74 years for females. Given the levels of disease in 2001, the risk of getting liver cancer before the age of 75 years was 1 in 504 for males and 1 in 623 for females (Table 7a). Cancer of the liver is predominantly a disease in the older population with few cases diagnosed before the age of 60 years. The age-specific rates were generally higher in males than females (Figure 7a). Prevalence In Northern ...

Integrative analysis of multiple gene expression profiles applied to liver cancer study Jung Kyoon Choi a,b , Jong Young Choi c , Dae Ghon Kim d , Dong Wook Choi e , Bu Yeo Kim e , Kee Ho Lee e , Young Il Yeom f , Hyang Sook Yoo f , Ook Joon Yoo b , Sangsoo Kim a, * a National Genome Information Center, Korea Research Institute of Bioscience and Biotechnology, Yuseong-gu, Eoeun-dong 52, Daejeon 305-333, Republic of Korea b Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea c Kangnam St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea d Division of Gastroenterology and Hepatology, Chonbuk National University ...

Annual cancer incidence and death rates per 100,000 South Australians by age, 1991-2001 Cancer site: Liver Males 0.0 10.0 20.0 30.0 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80* Age (yrs.) R a te/ 1 00, 000 Incidence Mortality Females 0.0 2.5 5.0 7.5 10.0 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80* Age (yrs.) R a te/ 100, 000 Incidence Mortality Both 0.0 5.0 10.0 15.0 20.0 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80* Age (yrs.) R a te/ 100, 000 Incidence Mortality

Rachel's Environment & Health News #73 - Study Of Dioxin-Exposed Humans Reveals Cancer , Birth Defects, Liver And Cardiovascular Damage April 17, 1988 A new study of Vietnam veterans, conducted by Air Force physicians, links dioxin exposure to increases in cancer , birth defects, psychological damage, liver damage, cardiovascular deterioration, and degeneration of the endocrine system. The new work stops short of saying dioxin exposures CAUSED the observable health damage among dioxin-exposed vets, but it explicitly reverses the conclusions of a 1984 Air Force study which said dioxin exposures had been shown to be harmless. The study is continuing, and will begin using sensitive new blood tests to determine past exposures to dioxin; future study may be able to pin down, or rule out, direct causal effects. In the meantime, advocates of mass burn incinerators and other dioxinproducing ...

liver cancer The effects of CEACAM1 on desmosomal organization in prostate and liver cancer Nikia Laurie, Jeanne Brown, Marie Carreiro, Megan Comegys and Douglas Hixson Brown University/Rhode Island Hospital, Department of Medicine, Providence, RI CEACAM1 is a member of the CEA family of Ig-like adhesion molecules. The two major splice variants (CEACAM1-4L and CEACAM1-4S) show downregulated expression in prostate and liver carcinomas. Restoration of CEACAM1-4L but not CEACAM1-4S expression results in tumor suppression. We have previously shown that restoration of CEACAM1-4L expression in PC-3 (prostate carcinoma) cells results in loss of tumorigenicity (growth suppression) when injected subcutaneously into nude mice. Current studies show that 1682A ( liver carcinoma) CEACAM1-4L cells injected into the intraperitoneal cavity of rats show no growth at three weeks, while ...

196 Annals Academy of Medicine Liver Resection for Colorectal Metastases—C S C Teh & L L P J Ooi * Clinical Associate Department of General Surgery Singapore General Hospital ** Chief of Hepatobiliary Surgery Unit and Deputy Head Department of Surgical Oncology, National Cancer Centre, Singapore Senior Consultant Department of General Surgery, Singapore General Hospital Clinical Associate Professor National University of Singapore Address for Reprints: Dr London Lucien Ooi, Department of Surgical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610. E-mail: dsoopj@nccs.com.sg Hepatic Resection for Colorectal Metastases to the Liver : The National Cancer Centre/Singapore General Hospital Experience C S C Teh,* MD, DPBS , L L P J Ooi,** FAMS, FRCS (Edin & Glas), MD Abstract ...